Top

Published in:

01-11-2017 | Original Article

The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients

Authors: Mohammad Kazzem Gheybi, Shokrollah Farrokhi, Mohammad Reza Ravanbod, Afshin Ostovar, Valiollah Mehrzad, Pardis Nematollahi

Published in: Breast Cancer | Issue 6/2017

Abstract

Background

T regulatory cells (Tregs) are known to negatively control immune response. The frequency of these cells was inversely correlated with clinical outcomes of breast cancer. CD19⁺CD24^hiCD38^hi cells also play a critical role in inflammation and autoimmune disease. However, their function in tumor immune response is less studied. In this study we aimed to determine the role of CD19⁺CD24^hiCD38^hi cells and some other clinicopathological variables in increasing the proportion of Tregs in breast cancer patients.

Methods

We selected 47 patients with invasive ductal breast carcinoma and 50 healthy controls and obtained their blood samples.

Results

The proportion of circulating CD4⁺CD25⁺Foxp3⁺ Tregs and CD19⁺CD24^hiCD38^hi cells was significantly increased in breast cancer patients. We also found that increased proportion of Tregs in breast cancer is correlated with HER2 amplification, advanced clinical stages, serum TGF-β1 and increased CD19⁺CD24^hiCD38^hi cells in the peripheral blood.

Conclusion

Altogether, our data suggest that as much as Tregs, CD19⁺CD24^hiCD38^hi B cells could also have a part in the suppression of immune response in breast cancer.

Zob D, Vasilescu M, Gruia M, Anghel R. Breast cancer. Screening criteria. Chirurgia (Bucur). 2013;108(4):557–62.

Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010;29(4):569–79. doi:10.1007/s10555-010-9247-y.CrossRefPubMed

Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, Macmillan D, Ellis IO. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670–80. doi:10.1002/cncr.26711.CrossRefPubMed

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.CrossRefPubMed

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. doi:10.1016/j.cell.2010.01.025.CrossRefPubMedPubMedCentral

Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11(1):7–13. doi:10.1038/ni.1818.CrossRefPubMed

Rech AJ, Mick R, Kaplan DE, Chang KM, Domchek SM, Vonderheide RH. Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother. 2010;59(4):599–607. doi:10.1007/s00262-009-0780-x.CrossRefPubMed

Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3 + regulatory T cells. Nat Rev Immunol. 2011;11(2):119–30. doi:10.1038/nri2916.CrossRefPubMedPubMedCentral

Wilke CM, Wu K, Zhao E, Wang G, Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer. 2010;127(4):748–58. doi:10.1002/ijc.25464.PubMed

10.

Li YQ, Liu FF, Zhang XM, Guo XJ, Ren MJ, Fu L. Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer. PLoS One. 2013;8(10):e76379. doi:10.1371/journal.pone.0076379.CrossRefPubMedPubMedCentral

11.

Yuan XL, Chen L, Li MX, Dong P, Xue J, Wang J, Zhang TT, Wang XA, Zhang FM, Ge HL, Shen LS, Xu D. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol. 2010;134(3):277–88. doi:10.1016/j.clim.2009.10.005.CrossRefPubMed

12.

Decker T, Fischer G, Bucke W, Bucke P, Stotz F, Gruneberger A, Gropp-Meier M, Wiedemann G, Pfeiffer C, Peschel C, Gotze K. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J Cancer Res Clin Oncol. 2012;138(11):1945–50. doi:10.1007/s00432-012-1258-3.CrossRefPubMed

13.

14.

Ouyang W, Beckett O, Ma Q, Li MO. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity. 2010;32(5):642–53. doi:10.1016/j.immuni.2010.04.012.CrossRefPubMedPubMedCentral

15.

Gupta S, Joshi K, Wig JD, Arora SK. Intratumoral FOXP3 expression in infiltrating breast carcinoma: its association with clinicopathologic parameters and angiogenesis. Acta Oncol. 2007;46(6):792–7. doi:10.1080/02841860701233443.CrossRefPubMed

16.

Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology. 2013;2(7):e25443. doi:10.4161/onci.25443.CrossRefPubMedPubMedCentral

17.

Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med. 1996;184(6):2271–8.CrossRefPubMedPubMedCentral

18.

Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010;32(1):129–40. doi:10.1016/j.immuni.2009.11.009.CrossRefPubMed

19.

Lemoine S, Morva A, Youinou P, Jamin C. Human T cells induce their own regulation through activation of B cells. J Autoimmun. 2011;36(3–4):228–38. doi:10.1016/j.jaut.2011.01.005.CrossRefPubMed

20.

Horikawa M, Minard-Colin V, Matsushita T, Tedder TF. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest. 2011;121(11):4268–80. doi:10.1172/JCI59266.CrossRefPubMedPubMedCentral

21.

Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA. 2011;108(26):10662–7. doi:10.1073/pnas.1100994108.CrossRefPubMedPubMedCentral

22.

Wang WW, Yuan X, Chen H, Xie G, Ma Y, Zheng Y, Zhou Y, Shen L. CD19 + CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer. Oncotarget. 2015;6(32):33486–99.CrossRefPubMedPubMedCentral

23.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.CrossRefPubMed

24.

Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207. doi:10.1186/bcr2607.CrossRefPubMedPubMedCentral

25.

Murthy V, Chamberlain RS. Further expansion of the AJCC/UICC breast cancer staging system to encompass unique problems in the developing world. Ann Surg Oncol. 2011;18(Suppl 3):S278–80. doi:10.1245/s10434-011-1649-8.CrossRefPubMed

26.

Miyoshi H, Uchida K, Taniguchi T, Yazumi S, Matsushita M, Takaoka M, et al. Circulating naive and CD4 + CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas. 2008;36(2):133–40.CrossRefPubMed

27.

Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28(29):4531–8. doi:10.1200/JCO.2009.27.2146.CrossRefPubMedPubMedCentral

28.

Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014;124(13):2034–45. doi:10.1182/blood-2014-04-571125.CrossRefPubMedPubMedCentral

29.

Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN, Rigatos G, Papamichail M. CD4 + CD25 + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007;13(9):2714–21. doi:10.1158/1078-0432.CCR-06-2347.CrossRefPubMed

30.

Gheybi MK, Baradaran A, Mohajeri MR, Ostovar A, Hajalikhani P, Farrokhi S. Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients. APMIS. 2016;124(5):365–71.CrossRefPubMed

31.

Zhu S, Lin J, Qiao G, Xu Y, Zou H. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients. Tumour Biol. 2015;36(10):7907–13. doi:10.1007/s13277-015-3507-y.CrossRefPubMed

32.

Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153–8. doi:10.1200/JCO.2007.15.5986.CrossRefPubMed

33.

Shevach EM, Davidson TS, Huter EN, Dipaolo RA, Andersson J. Role of TGF-Beta in the induction of Foxp3 expression and T regulatory cell function. J Clin Immunol. 2008;28(6):640–6. doi:10.1007/s10875-008-9240-1.CrossRefPubMed

34.

Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol. 2013;34(4):169–73. doi:10.1016/j.it.2012.10.007.CrossRefPubMed

35.

Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, Rosenblatt JD. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother. 2013;62(1):87–99. doi:10.1007/s00262-012-1313-6.CrossRefPubMed

36.

Schwartz M, Zhang Y, Rosenblatt JD. B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer. 2016;4:40.CrossRefPubMedPubMedCentral

Title: The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients
Authors: Mohammad Kazzem Gheybi
Shokrollah Farrokhi
Mohammad Reza Ravanbod
Afshin Ostovar
Valiollah Mehrzad
Pardis Nematollahi
Publication date: 01-11-2017
Publisher: Springer Japan
Published in: Breast Cancer / Issue 6/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-017-0775-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2017

Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer

A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer

Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size

Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy

Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer

Acknowledgement to reviewers 2017

Keynote webinar | Spotlight on antibody–drug conjugates in cancer